Panels: ThunderBoltsTM Cancer Panel (Interrogate mutations/hotspots in 50 oncogenes, tumor suppressors and drug resistance markers); ThunderBoltsTMMyeloid Panel (Target mutations/hotspots in 49 genes implicated in AML, MDS, MPN and myeloma diseases, including challenging genes such as CEBPA and NOTCH1. This evidence concerns the gene NOTCH1 and cancer.